Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20:404–17. https://doi.org/10.1038/s41569-022-00820-8.

Article  PubMed  Google Scholar 

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8. https://doi.org/10.1161/01.STR.22.8.983.

Article  CAS  PubMed  Google Scholar 

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to prevent stroke in patients who have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146:857–67. https://doi.org/10.7326/0003-4819-146-12-200706190-00007.

Article  PubMed  Google Scholar 

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2024;149:e1–156. https://doi.org/10.1161/CIR.0000000000001193.

Article  PubMed  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612.

Article  PubMed  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.

Article  CAS  PubMed  Google Scholar 

Hsu JC, Maddox TM, Kennedy KF, Katz DF, Marzec LN, Lubitz SA, et al. Oral anticoagulant therapy prescription in patients with Atrial Fibrillation across the Spectrum of Stroke Risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1:55–62. https://doi.org/10.1001/jamacardio.2015.0374.

Article  PubMed  Google Scholar 

Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in Use of oral anticoagulants in older adults with newly diagnosed Atrial Fibrillation, 2010–2020. JAMA Netw Open. 2022;5:e2242964. https://doi.org/10.1001/jamanetworkopen.2022.42964.

Article  PubMed  PubMed Central  Google Scholar 

●●Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from Hemostasis. J Am Coll Cardiol. 2021;78:625–31. https://doi.org/10.1016/j.jacc.2021.06.010. A comprehensive review of the factor XI hypothesis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

●●Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81:771–9. https://doi.org/10.1016/j.jacc.2022.11.057. A comprehensive review of the factor XI hypothesis and current factor XI pathway inhibitor programs across clinical indications..

Fredenburgh JC, Weitz JI. News at XI: moving beyond factor xa inhibitors. J Thromb Haemost. 2023;21:1692–702. https://doi.org/10.1016/j.jtha.2023.04.021.

Article  PubMed  Google Scholar 

Occhipinti G, Laudani C, Spagnolo M, Finocchiaro S, Mazzone PM, Faro DC, et al. Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J - Cardiovasc Pharmacother. 2024;10:245–58. https://doi.org/10.1093/ehjcvp/pvae002.

Article  PubMed  Google Scholar 

Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129:1210–5. https://doi.org/10.1182/blood-2016-09-742262.

Article  CAS  PubMed  Google Scholar 

Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of rare bleeding disorders. J Thromb Haemost. 2012;10:615–21. https://doi.org/10.1111/j.1538-7836.2012.04653.x.

Article  CAS  PubMed  Google Scholar 

Georgi B, Mielke J, Chaffin M, Khera AV, Gelis L, Mundl H, et al. Leveraging Human Genetics to Estimate Clinical Risk reductions Achievable by inhibiting factor XI. Stroke. 2019;50:3004–12. https://doi.org/10.1161/STROKEAHA.119.026545.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI Deficiency in Ashkenazi jews in Israel. N Engl J Med. 1991;325:153–8. https://doi.org/10.1056/NEJM199107183250303.

Article  CAS  PubMed  Google Scholar 

Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu M, Smith PL, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695–702. https://doi.org/10.1111/j.1538-7836.2005.01236.x.

Article  CAS  PubMed  Google Scholar 

Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJT, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009;113:936–44. https://doi.org/10.1182/blood-2008-06-163675.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, et al. Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates. Arterioscler Thromb Vasc Biol. 2013;33:1670–8. https://doi.org/10.1161/ATVBAHA.113.301282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

●●Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 2022;399:1383–90. https://doi.org/10.1016/S0140-6736(22)00456-1. A phase 2 randomized trial of asundexian, a small molecule oral factor XIa inhibitor, compared with apixaban, in 755 patients with atrial fibrillation followed for 12 weeks.

Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400:997–1007. https://doi.org/10.1016/S0140-6736(22)01588-4.

Article  CAS  PubMed  Google Scholar 

Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, Multicenter A, et al. Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse Cardiovascular outcomes after Acute myocardial infarction. Circulation. 2022;146:1196–206. https://doi.org/10.1161/CIRCULATIONAHA.122.061612.

Article  CAS  PubMed  Google Scholar 

Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the Prevention of venous thromboembolism. N Engl J Med. 2021;385:2161–72. https://doi.org/10.1056/NEJMoa2113194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of Osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT Randomized Clinical Trial. JAMA. 2020;323:130–9. https://doi.org/10.1001/jama.2019.20687.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verhamme P, Yi AB, Segers A, Salter J, Bloomfield D, Büller HR, et al. Abelacimab for Prevention of venous thromboembolism. N Engl J Med. 2021;385:609–17. https://doi.org/10.1056/NEJMoa2105872.

Article  CAS  PubMed  Google Scholar 

Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138:2173–84. https://doi.org/10.1182/blood.2021011725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

●●Ruff CT, AZALEA-TIMI 71 Steering Committee. Abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. Circulation,. 2024;148:e282–317. https://doi.org/10.1161/CIR.0000000000001200. A phase 2 randomized trial of abelacimab, an injectable monoclonal antibody inhibitor of factor XI/XIa, compared with rivaroxaban in 1,287 patients with atrial fibrillation followed for a median of 1.8 years.

Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2022;7:200–9. https://doi.org/10.1016/j.ekir.2021.11.011.

Article  PubMed